US · STRO
Sutro Biopharma, Inc.
- Sector
- Healthcare · Biotechnology
- Headquarters
- South San Francisco, CA 94080
- Website
- sutrobio.com
Price · as of 2024-12-31
$35.59
Market cap 174.27M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $6.00 | -83.14% |
| Intrinsic Value(DCF) | $6.00 | -83.14% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | $1,447.09 | +3,966.01% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | $0.00 | $131.87 | |||
| 2018 | $94.00 | $750.62 | $40.91 | $0.00 | $255.69 |
| 2019 | $95.30 | $3,377.70 | $16.15 | $0.00 | $0.00 |
| 2020 | $234.10 | $121.02 | $74.77 | $52.62 | $0.00 |
| 2021 | $79.60 | $31.84 | $37.70 | $0.00 | $0.00 |
| 2022 | $51.30 | $205.64 | $15.97 | $0.00 | $0.00 |
| 2023 | $46.70 | $6,929.62 | $103,250.11 | $0.00 | $0.00 |
| 2024 | $15.00 | $6.00 | $0.00 | $0.00 | $1,447.09 |
AI valuation
Our deep-learning model estimates Sutro Biopharma, Inc.'s (STRO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $6.00
- Current price
- $35.59
- AI upside
- -83.14%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$6.00
-83.14% upside
Graham-Dodd
—
— upside
Graham Formula
$1,447.09
+3,966.01% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| STRO | Sutro Biopharma, Inc. | $35.59 | 174.27M | -83% | -83% | — | +3,966% | -0.51 | 2.58 | 1.86 | 0.99 | -0.76 | 2.58 | 88.37% | -384.34% | -366.62% | -234.19% | 108.03% | -53.02% | 0.52 | -7.67 | 2.60 | 2.47 | 0.93 | 6629.00% | -5964.00% | 6789.00% | -168.89% | -1.45 | 88.18% | 0.00% | 0.00% | 114.12% | 0.75 | 0.92 | -2.88 | -3.86 |
| ADVM | Adverum Biotechnologies, … | $4.36 | 96.26M | +263% | -58% | — | +9,149% | -0.69 | 1.28 | 90.60 | -0.44 | -0.30 | 1.28 | -265.30% | -15315.90% | -13092.70% | -169.83% | -313.49% | -74.21% | 1.30 | — | 5.73 | 5.49 | -0.24 | 22772.00% | -7222.00% | 124.00% | -102.48% | -4.04 | -190.05% | 0.00% | 0.00% | 0.00% | -0.37 | -0.61 | 56.62 | -9.89 |
| ARTV | Artiva Biotherapeutics, I… | $5.82 | 142.85M | +335% | -18% | — | +3,479% | -2.00 | 0.70 | 520.26 | 0.62 | -0.59 | 0.70 | 100.00% | -26805.58% | -23303.98% | -530.93% | 65.16% | -41.55% | 0.08 | — | 15.39 | 15.15 | 0.40 | 33697.00% | -9925.00% | 984.00% | -42.63% | -4.49 | 53.92% | 0.00% | 0.00% | 3.20% | 0.60 | 0.73 | -161.31 | 1.72 |
| CNTB | Connect Biopharma Holding… | $2.47 | 138.08M | — | — | — | — | -3.00 | 0.51 | 1.80 | 2.14 | — | 0.51 | 100.00% | -86.24% | -60.03% | -16.18% | 242.61% | -13.76% | 0.00 | — | 11.46 | 11.20 | 3.58 | -7407.00% | — | -4948.00% | -51.91% | -2.79 | 263.24% | 0.00% | 0.00% | 0.00% | 2.08 | 1.91 | -1.79 | -1.11 |
| DTIL | Precision BioSciences, In… | $4.20 | 55.67M | +1,686% | -46% | +221% | +1,082% | 4.94 | 0.63 | 0.52 | -1.54 | — | 0.63 | 100.00% | -38.08% | 10.43% | 19.05% | 78.77% | 4.84% | 0.53 | -14.68 | 6.34 | 5.88 | -4.13 | -10652.00% | 4098.00% | -3206.00% | -165.83% | -3.90 | 176.73% | 0.00% | 0.00% | 0.00% | 0.80 | 0.36 | -0.30 | -4.11 |
| GUTS | Fractyl Health, Inc. Comm… | $0.47 | 33.88M | +4,277% | +19% | — | +4,370% | -0.89 | 2.16 | 660.15 | -0.61 | — | 2.16 | 46.24% | -100570.97% | -73864.52% | 46.32% | -484.68% | -74.55% | 2.20 | — | 3.63 | 3.41 | 0.05 | -1818.00% | -2250.00% | 5582.00% | -109.60% | -3.31 | -348.68% | 0.00% | 0.00% | 562.21% | -0.60 | -0.84 | 606.77 | -7.20 |
| IFRX | InflaRx N.V. | $0.92 | 62.33M | +5,018% | -48% | — | — | -1.32 | 0.99 | 367.43 | -0.95 | — | 0.99 | -1900.76% | -31973.69% | -27784.96% | -56.18% | -78.66% | -46.95% | 0.01 | -2566.39 | 5.06 | 1.30 | 0.39 | 0.00% | 16279.00% | 2826.00% | -79.79% | -3.43 | -72.12% | 0.00% | 0.00% | 9.72% | -0.82 | -0.89 | 261.45 | -5.01 |
| KLRS | Kalaris Therapeutics Inc | $10.46 | 195.63M | — | — | — | — | -0.84 | 0.44 | — | 1.17 | — | 0.44 | 0.00% | — | — | -172.12% | 207.85% | -96.44% | 0.00 | — | 22.63 | 22.58 | 2.01 | -7213.00% | — | 37909.00% | -136.96% | -12.92 | 254.68% | 0.00% | 0.00% | 232.88% | 1.25 | 1.02 | — | -3.17 |
| MGX | Metagenomi, Inc. Common S… | $1.52 | 57.07M | +1,047% | +86% | — | — | -0.99 | 0.33 | 1.48 | 1.50 | -6.69 | 0.33 | 100.00% | -170.00% | -149.26% | -34.69% | -676.50% | -22.64% | 0.19 | — | 6.91 | 6.69 | -0.22 | 1484.00% | 1684.00% | 1083.00% | -144.84% | -2.92 | -913.98% | 0.00% | 0.00% | 0.00% | 1.41 | 1.11 | -2.39 | -0.37 |
| PLRX | Pliant Therapeutics, Inc. | $1.30 | 79.88M | +1,747% | — | — | — | -0.47 | 0.32 | — | 0.96 | -1.78 | 0.32 | 0.00% | — | — | -54.09% | 61060.16% | -46.27% | 0.20 | -75.52 | 10.91 | 10.78 | 0.05 | 2618.00% | -10000.00% | 3587.00% | -162.48% | -4.68 | 42607.22% | 0.00% | 0.00% | 0.00% | 0.86 | 1.24 | — | -2.77 |
| STTK | Shattuck Labs, Inc. | $3.92 | 187.78M | +1,035% | -87% | — | — | -0.83 | 0.78 | 10.91 | 0.09 | — | 0.78 | 100.00% | -1408.27% | -1318.13% | -67.23% | -568.84% | -60.18% | 0.04 | — | 8.88 | 8.19 | 0.70 | -2732.00% | 24526.00% | -2580.00% | -97.02% | -6.79 | -427.68% | 0.00% | 0.00% | 0.00% | 0.09 | 0.12 | -1.25 | -4.52 |
About Sutro Biopharma, Inc.
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and non-Hodgkin lymphoma that is in Phase 1 clinical trials; and STRO-002, an ADC directed against folate receptor-alpha for patients with ovarian and endometrial cancers, which is in Phase 1 clinical trials. It has collaboration and license agreements with Merck Collaboration to develop research programs focusing on cytokine derivatives for cancer and autoimmune disorders; and Celgene Corporation to discover and develop bispecific antibodies and/or ADCs focused on the field of immuno-oncology. The company was formerly known as Fundamental Applied Biology, Inc. Sutro Biopharma, Inc. was incorporated in 2003 and is headquartered in South San Francisco, California.
- CEO
- Jane Chung
- Employees
- 269
- Beta
- 1.55
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($6.00 ÷ $35.59) − 1 = -83.14% (DCF, example).